Stargardt disease affects approximately 1:10,000 individuals and causes progressive, irreversible blindness. While primarily a juvenile disease, age of onset can range from childhood to adulthood. Although supportive care can help slow progression, there are currently no approved therapies and all patients are expected to reach legal blindness. Therefore, Stargardt disease represents an urgent unmet medical need.Oak Bay Biosciences, based in Victoria BC, is a preclinical biotechnology company with a goal to develop the first approved therapy for Stargardt disease.